Latest & greatest articles for carvedilol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on carvedilol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on carvedilol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for carvedilol

1. Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity

Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity 30292333 2018 11 16 1879-1913 122 11 2018 Dec 01 The American journal of cardiology Am. J. Cardiol. Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity. 1959-1964 S0002-9149(18)31738-7 10.1016/j.amjcard.2018.08.039 Anthracycline is a commonly prescribed antineoplastic agent. As a consequence of the growing number of cancer survivors, the incidence of anthracycline-induced (...) cardiotoxicity is increasing. However, the optimal primary preventive strategy is lacking. Therefore, we conducted a meta-analysis of all randomized controlled trials to evaluate the efficacy of carvedilol for the primary prevention of anthracycline-induced cardiotoxicity. A comprehensive search of electronic databases was conducted. The primary and secondary outcomes were the occurrence of low left ventricular ejection fraction, and the absolute change in left ventricular ejection fraction (LVEF

2018 EvidenceUpdates

2. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. (PubMed)

Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. BACKGROUND: Non-selective beta-blockers are recommended for the prevention of bleeding in people with cirrhosis, portal hypertension and gastroesophageal varices. Carvedilol is a non-selective beta-blocker with additional intrinsic alpha 1 -blocking effects, which may be superior to traditional, non-selective beta-blockers in reducing portal pressure and, therefore, in reducing (...) the risk of upper gastrointestinal bleeding. OBJECTIVES: To assess the beneficial and harmful effects of carvedilol compared with traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. SEARCH METHODS: We combined searches in the Cochrane Hepato-Biliary's Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, LILACS, and Science Citation Index with manual searches. The last search update was 08 May 2018

2018 Cochrane

3. Carvedilol

Carvedilol Top results for carvedilol - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for carvedilol The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

2018 Trip Latest and Greatest

4. Endothelial Phenotype Evoked by Low Dose Carvedilol in Pulmonary Hypertension. (PubMed)

Endothelial Phenotype Evoked by Low Dose Carvedilol in Pulmonary Hypertension. 30619887 2019 01 11 2297-055X 5 2018 Frontiers in cardiovascular medicine Front Cardiovasc Med Endothelial Phenotype Evoked by Low Dose Carvedilol in Pulmonary Hypertension. 180 10.3389/fcvm.2018.00180 Background: The therapeutic benefits of β-blockers are well established in left heart failure. The Pulmonary Arterial Hypertension Treatment with Carvedilol for Heart Failure [PAHTCH] study showed safety and possible (...) benefit of carvedilol in pulmonary arterial hypertension (PAH) associated right heart failure over 6 months. This study aims at evaluating the short-term cardiovascular effects and early mechanistic biomarkers of carvedilol therapy. Methods: Thirty patients with pulmonary hypertension (PH) received low dose carvedilol (3.125 mg twice daily) for 1 week prior to randomization to placebo, low-dose, or dose-escalating carvedilol therapy. Echocardiography was performed at baseline and 1 week. Exercise

Full Text available with Trip Pro

2018 Frontiers in cardiovascular medicine

5. A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis (PubMed)

A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis 27575713 2016 08 30 2017 02 20 1572-0241 111 11 2016 Nov The American journal of gastroenterology Am. J. Gastroenterol. A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. 1582-1590 10.1038/ajg.2016.327 Propranolol has been used (...) as prophylaxis for variceal bleeding in patients with cirrhosis. More recent data suggest that carvedilol may be more effective for reducing the hepatic venous pressure gradient (HVPG) than propranolol. The primary aim of this study was to evaluate the hemodynamic response to carvedilol compared with propranolol. A total of 110 patients with a baseline HVPG value >12 mm Hg were allocated randomly to receive either carvedilol or propranolol. The HVPG measurement was repeated after 6 weeks of daily medication

2016 EvidenceUpdates

6. Carvedilol

Carvedilol USE OF CARVEDILOL IN PREGNANCY 0344 892 0909 USE OF CARVEDILOL IN PREGNANCY (Date of issue: February 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Carvedilol is a non-cardioselective beta-adrenoceptor blocking drug licensed for the treatment of hypertension, angina pectoris (...) and symptomatic chronic heart failure (CHF). There are no studies of rates of specific pregnancy outcomes following gestational exposure to carvedilol. An evidence-based assessment of the potential risks of congenital malformation, spontaneous abortion, stillbirth, intrauterine growth restriction (IUGR), preterm delivery and adverse neurodevelopmental effects following in utero exposure is therefore not possible and women should be made aware of this lack of data. Studies of beta-blockers as a class have

2014 UK Teratology Information Service

7. Meta-Analysis of Carvedilol Versus Beta 1 Selective Beta-Blockers (Atenolol, Bisoprolol, Metoprolol, and Nebivolol) (PubMed)

Meta-Analysis of Carvedilol Versus Beta 1 Selective Beta-Blockers (Atenolol, Bisoprolol, Metoprolol, and Nebivolol) 23290925 2013 04 17 2015 11 19 1879-1913 111 5 2013 Mar 01 The American journal of cardiology Am. J. Cardiol. Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol). 765-9 10.1016/j.amjcard.2012.11.031 S0002-9149(12)02464-2 Because carvedilol is a unique vasodilating β blocker (BB) exerting antioxidant activity (...) and pleiotropic effects, it was theorized that it may confer more potent beneficial effects on cardiovascular mortality and morbidity in acute myocardial infarction (AMI) and heart failure (HF) settings. A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital

2013 EvidenceUpdates

8. BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial

BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2011 PedsCCM Evidence-Based Journal Club

9. Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure (PubMed)

Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure 21129714 2011 01 07 2011 04 05 2013 11 21 1879-1913 107 2 2011 Jan 15 The American journal of cardiology Am. J. Cardiol. Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure. 215-9 10.1016 (...) receptor antagonist bisoprolol compared to the less selective β blocker carvedilol in preventing postdischarge AF after CABG in patients with decreased left ventricular function. Three hundred twenty patients (231 men, 89 women, mean age 66 ± 10 years) with ejection fraction <40% who underwent CABG and were then referred to an in-hospital cardiac rehabilitation program were randomized to receive bisoprolol (n = 160) or carvedilol (n = 160) starting 4 to 5 days after surgery. Bisoprolol was started

2011 EvidenceUpdates

10. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients (PubMed)

Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients 18564334 2009 02 13 2009 11 02 2013 11 21 1463-1326 11 3 2009 Mar Diabetes, obesity & metabolism Diabetes Obes Metab Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. 234-8 10.1111/j.1463-1326.2008.00927.x Vasoconstricting beta-blocker use is associated with a reduction in HDL cholesterol, higher triglyceride, total cholesterol (...) and LDL cholesterol levels, whereas carvedilol, a vasodilating beta-blocker, has not been associated with these effects. To compare in a randomized, double-blind study, the effects of the beta 1-blocker metoprolol tartrate with the combined alpha 1, beta-blocker carvedilol on serum lipid concentrations. A prospective randomized, double-blind, parallel-group trial compared the effects of carvedilol and metoprolol on total cholesterol, triglycerides, calculated LDL, HDL and non-HDL cholesterol levels at baseline

2009 EvidenceUpdates

11. Carvedilol was more effective than metoprolol for preventing cardiovascular events in heart failure

Carvedilol was more effective than metoprolol for preventing cardiovascular events in heart failure Carvedilol was more effective than metoprolol for preventing cardiovascular events in heart failure | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword (...) Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Carvedilol was more effective than metoprolol for preventing cardiovascular events in heart failure Article Text Therapeutics Carvedilol was more effective than metoprolol for preventing cardiovascular events in heart failure Statistics from Altmetric.com No Altmetric data available for this article

2008 Evidence-Based Medicine (Requires free registration)

12. Effect of exercise training and carvedilol treatment on cardiac function and structure in mice with sympathetic hyperactivity-induced heart failure. (PubMed)

Effect of exercise training and carvedilol treatment on cardiac function and structure in mice with sympathetic hyperactivity-induced heart failure. 18820772 2008 09 29 2009 05 22 2016 10 18 1414-431X 41 9 2008 Sep Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas Braz. J. Med. Biol. Res. Effect of exercise training and carvedilol treatment on cardiac function and structure in mice with sympathetic hyperactivity-induced heart (...) failure. 812-7 S0100-879X2008000900012 The present investigation was undertaken to study the effect of beta-blockers and exercise training on cardiac structure and function, respectively, as well as overall functional capacity in a genetic model of sympathetic hyperactivity-induced heart failure in mice (alpha(2A)/alpha(2C)ArKO). alpha(2A)/alpha(2C)ArKO and their wild-type controls were studied for 2 months, from 3 to 5 months of age. Mice were randomly assigned to control (N = 45), carvedilol-treated (N

2008 Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas

13. Impact of carvedilol on the serum lipid profile

Impact of carvedilol on the serum lipid profile Impact of carvedilol on the serum lipid profile Impact of carvedilol on the serum lipid profile Sharp RP, Sirajuddin R, Sharief IM CRD summary This review concluded that β 1 -selective antagonists worsened the lipid profile compared to carvedilol and that it was unclear whether carvedilol independently made an improvement or had a neutral effect. The review had several methodological flaws and the authors' conclusions are not likely to be reliable (...) . Authors' objectives To assess the impact of carvedilol on the serum lipid profile. Searching MEDLINE and International Pharmaceutical Abstracts were searched for published studies between 1966 and December 2007. Search terms were reported. Study selection Studies that evaluated the impact of carvedilol on the lipid profile were selected for inclusion. Studies of off-label use of carvedilol were excluded. Patients in included studies had hypertension or diabetes mellitus. Comparator treatments included

2008 DARE.

14. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. (PubMed)

Carvedilol for children and adolescents with heart failure: a randomized controlled trial. 17848651 2007 09 12 2007 09 14 2016 10 17 1538-3598 298 10 2007 Sep 12 JAMA JAMA Carvedilol for children and adolescents with heart failure: a randomized controlled trial. 1171-9 Although beta-blockers improve symptoms and survival in adults with heart failure, little is known about these medications in children and adolescents. To prospectively evaluate the effects of carvedilol in children (...) and adolescents with symptomatic systemic ventricular systolic dysfunction. A multicenter, randomized, double-blind, placebo-controlled study of 161 children and adolescents with symptomatic systolic heart failure from 26 US centers. In addition to treatment with conventional heart failure medications, patients were assigned to receive placebo or carvedilol. Enrollment began in June 2000 and the last dose was given in May 2005 (each patient received medication for 8 months). Patients were randomized in a 1:1

Full Text available with Trip Pro

2007 JAMA

15. Carvedilol reduced mortality and hospital admission in severe chronic heart failure, regardless of pretreatment systolic BP

Carvedilol reduced mortality and hospital admission in severe chronic heart failure, regardless of pretreatment systolic BP Carvedilol reduced mortality and hospital admission in severe chronic heart failure, regardless of pretreatment systolic BP | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Carvedilol reduced mortality and hospital admission in severe chronic heart failure, regardless of pretreatment systolic BP Article Text Therapeutics Carvedilol reduced mortality and hospital admission in severe chronic heart failure, regardless

Full Text available with Trip Pro

2006 Evidence-Based Medicine (Requires free registration)

16. Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure

Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure Article Text Therapeutics Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure Free Curt D Furberg , MD, PhD , Bruce M Psaty , MD, PhD Statistics

Full Text available with Trip Pro

2005 Evidence-Based Medicine (Requires free registration)

17. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. (PubMed)

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. 15536109 2004 11 10 2004 11 15 2016 10 17 1538-3598 292 18 2004 Nov 10 JAMA JAMA Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. 2227-36 Beta-blockers have been shown to decrease cardiovascular risk in patients with hypertension and type 2 diabetes mellitus (DM); however (...) , some components of the metabolic syndrome are worsened by some beta-blockers. To compare the effects of beta-blockers with different pharmacological profiles on glycemic and metabolic control in participants with DM and hypertension receiving renin-angiotensin system (RAS) blockade, in the context of cardiovascular risk factors. A randomized, double-blind, parallel-group trial (The Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives [GEMINI]) conducted between

Full Text available with Trip Pro

2004 JAMA

18. Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan

Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan Inomata T, Izumi T, Kobayashi M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two treatments for the care of chronic heart failure (CHF) were under evaluation. The treatments compared were the addition of carvedilol to conventional therapies and conventional therapies alone. The conventional therapies included the concomitant use of angiotensin-converting enzyme (ACE) inhibitors, diuretics and digitalis. The treatment regimes were low-dose (5 mg/day

2004 NHS Economic Evaluation Database.

19. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. (PubMed)

Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. 12585949 2003 02 14 2003 02 25 2016 10 17 0098-7484 289 6 2003 Feb 12 JAMA JAMA Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. 712-8 Beta-blockers remain underused despite their established utility for improving outcome in heart failure. Concerns that initiation of treatment produces few immediate benefits and may (...) have important risks may be deterring widespread use. To evaluate the early effects of the beta-blocker carvedilol in patients with severe heart failure. Randomized, double-blind, placebo-controlled trial conducted from October 28, 1997, to March 20, 2000, at 334 hospital centers in 21 countries among 2289 patients with symptoms of heart failure at rest or with minimal exertion who were clinically euvolemic and had a left ventricular ejection fraction of less than 25%. Patients were randomly

2003 JAMA

20. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. (PubMed)

Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. 12853194 2003 07 10 2003 07 23 2015 06 16 1474-547X 362 9377 2003 Jul 05 Lancet (London, England) Lancet Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. 14-21 The improvement in left-ventricular ejection fraction (...) (LVEF) in response to beta blockers is heterogeneous in patients with heart failure due to ischaemic heart disease, possibly indicating variations in the myocardial substrate underlying left-ventricular dysfunction. We investigated whether improvement in LVEF was associated with the volume of hibernating myocardium (viable myocardium with contractile failure). We did a double-blind, randomised trial to compare placebo and carvedilol for 6 months in individuals with stable, chronic heart failure due

2003 Lancet